MedTrace Logo

Comparison of HR011408 and NovoRapid® in Subjects With Diabetics

NCT06375031 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-05-21

No results posted yet for this study

Summary

The objective of the study is to compare the pharmacokinetics and pharmacodynamics between HR011408 and NovoRapid® in Subjects with Diabetics.

Conditions

Interventions

DRUG

HR011408 injection; HR011408 injection Placebo

Medication regimen-A: HR011408 injection, ante cibum; HR011408 injection Placebo , post cibum

DRUG

NovoRapid®; HR011408 injection Placebo

Medication regimen-B: NovoRapid®, ante cibum; HR011408 injection Placebo, post cibum

DRUG

HR011408 injection Placebo; HR011408 injection

Medication regimen-C: HR011408 injection Placebo, ante cibum: HR011408 injection, post cibum

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-31
Primary Completion
2024-07-01
Completion
2024-07-15

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06375031 on ClinicalTrials.gov